VEGFA and neoplasm: Additionally, targeting the b1 domain of Nrp1 may compromise TGFβ and VEGF effects on myeloid cells, T cells and cancer stem cells, all of which are critical effectors in tumor progression, treatment resistance and tumor recurrence.